Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 102 entries
Sorted by: Best Match Show Resources per page
An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major: Retraction.

Therapeutic drug monitoring

[No authors listed]
PMID: 30768496
Ther Drug Monit. 2019 Apr;41(2):256. doi: 10.1097/FTD.0000000000000607.

No abstract available.

Cite
An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major: Retraction. Ther Drug Monit. 2019;41(2):256doi: 10.1097/FTD.0000000000000607.
(2019). An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major: Retraction. Therapeutic drug monitoring, 41(2), 256. https://doi.org/10.1097/FTD.0000000000000607
"An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major: Retraction." Therapeutic drug monitoring vol. 41,2 (2019): 256. doi: https://doi.org/10.1097/FTD.0000000000000607
An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major: Retraction. Ther Drug Monit. 2019 Apr;41(2):256. doi: 10.1097/FTD.0000000000000607. PMID: 30768496.
Copy Download .nbib Format: NLM
The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study: Erratum.

Therapeutic drug monitoring

[No authors listed]
PMID: 29746436
Ther Drug Monit. 2018 Jun;40(3):381. doi: 10.1097/FTD.0000000000000527.

No abstract available.

Cite
The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study: Erratum. Ther Drug Monit. 2018;40(3):381doi: 10.1097/FTD.0000000000000527.
(2018). The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study: Erratum. Therapeutic drug monitoring, 40(3), 381. https://doi.org/10.1097/FTD.0000000000000527
"The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study: Erratum." Therapeutic drug monitoring vol. 40,3 (2018): 381. doi: https://doi.org/10.1097/FTD.0000000000000527
The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study: Erratum. Ther Drug Monit. 2018 Jun;40(3):381. doi: 10.1097/FTD.0000000000000527. PMID: 29746436.
Copy Download .nbib Format: NLM
Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum.

Therapeutic drug monitoring

Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA.
PMID: 26829601
Ther Drug Monit. 2016 Apr;38(2):284. doi: 10.1097/FTD.0000000000000275. Epub 2016 Jan 21.

No abstract available.

Cite
Scott JR, Courter JD, Saldaña SN, et al. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum. Ther Drug Monit. 2016;38(2):284doi: 10.1097/FTD.0000000000000275.
Scott, J. R., Courter, J. D., Saldaña, S. N., Widemann, B. C., Fisher, M., Weiss, B., Perentesis, J., & Vinks, A. A. (2016). Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum. Therapeutic drug monitoring, 38(2), 284. https://doi.org/10.1097/FTD.0000000000000275
Scott, Jeffrey R, et al. "Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum." Therapeutic drug monitoring vol. 38,2 (2016): 284. doi: https://doi.org/10.1097/FTD.0000000000000275
Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum. Ther Drug Monit. 2016 Apr;38(2):284. doi: 10.1097/FTD.0000000000000275. Epub 2016 Jan 21. PMID: 26829601; PMCID: PMC4956590.
Copy Download .nbib Format: NLM
Erratum.

Therapeutic drug monitoring

[No authors listed]
PMID: 33297287
Ther Drug Monit. 2014 Feb;36(1):124. doi: 10.1097/FTD.0000000000000040.

No abstract available.

Cite
Erratum. Ther Drug Monit. 2014;36(1):124doi: 10.1097/FTD.0000000000000040.
(2014). Erratum. Therapeutic drug monitoring, 36(1), 124. https://doi.org/10.1097/FTD.0000000000000040
"Erratum." Therapeutic drug monitoring vol. 36,1 (2014): 124. doi: https://doi.org/10.1097/FTD.0000000000000040
Erratum. Ther Drug Monit. 2014 Feb;36(1):124. doi: 10.1097/FTD.0000000000000040. PMID: 33297287.
Copy Download .nbib Format: NLM
Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared To Phenytoin.

Therapeutic drug monitoring

Artul T, Henig I, Nassar L, Yehudai-Ofir D, Scherb MDI, Lurie Y, Efrati E, Zuckerman T, Kurnik D.
PMID: 34739424
Ther Drug Monit. 2021 Oct 26; doi: 10.1097/FTD.0000000000000938. Epub 2021 Oct 26.

BACKGROUND: Busulfan (Bu) conditioning used in hematopoietic stem cell transplantation (HSCT) may induce seizures, and prophylactic antiepileptic treatment is recommended. Following updated guidelines, in August 2019, the adult HSCT department of the Rambam Health Care Campus (Haifa, Israel) switched...

Cite
Artul T, Henig I, Nassar L, et al. Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared To Phenytoin. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000938.
Artul, T., Henig, I., Nassar, L., Yehudai-Ofir, D., Scherb, M. D. I., Lurie, Y., Efrati, E., Zuckerman, T., & Kurnik, D. (2021). Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared To Phenytoin. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000938
Artul, Tareq, et al. "Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared To Phenytoin." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000938
Artul T, Henig I, Nassar L, Yehudai-Ofir D, Scherb MDI, Lurie Y, Efrati E, Zuckerman T, Kurnik D. Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared To Phenytoin. Ther Drug Monit. 2021 Oct 26; doi: 10.1097/FTD.0000000000000938. Epub 2021 Oct 26. PMID: 34739424.
Copy Download .nbib Format: NLM
Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults: Erratum.

Therapeutic drug monitoring

[No authors listed]
PMID: 30883523
Ther Drug Monit. 2019 Apr;41(2):256. doi: 10.1097/FTD.0000000000000624.

No abstract available.

Cite
Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults: Erratum. Ther Drug Monit. 2019;41(2):256doi: 10.1097/FTD.0000000000000624.
(2019). Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults: Erratum. Therapeutic drug monitoring, 41(2), 256. https://doi.org/10.1097/FTD.0000000000000624
"Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults: Erratum." Therapeutic drug monitoring vol. 41,2 (2019): 256. doi: https://doi.org/10.1097/FTD.0000000000000624
Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults: Erratum. Ther Drug Monit. 2019 Apr;41(2):256. doi: 10.1097/FTD.0000000000000624. PMID: 30883523.
Copy Download .nbib Format: NLM
Development of a novel analytical method for determining trazodone in human plasma by LC-MS coupled with automatic 2-dimensional liquid chromatograph-mass spectrometer coupler 9500 and its application to therapeutic drug monitoring.

Therapeutic drug monitoring

Ding J, Zhang Y, Cui X, Zhao C, Zhang S.
PMID: 34469419
Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000921. Epub 2021 Aug 27.

BACKGROUND: Trazodone (TZD) is a tetracyclic serotonin antagonist and reuptake inhibitor that is used as a second-generation phenylpiperazine antidepressant. However, the plasma concentrations of TZD have shown individual variations in clinical practice. Quantification of TZD plasma concentrations may be...

Cite
Ding J, Zhang Y, Cui X, et al. Development of a novel analytical method for determining trazodone in human plasma by LC-MS coupled with automatic 2-dimensional liquid chromatograph-mass spectrometer coupler 9500 and its application to therapeutic drug monitoring. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000921.
Ding, J., Zhang, Y., Cui, X., Zhao, C., & Zhang, S. (2021). Development of a novel analytical method for determining trazodone in human plasma by LC-MS coupled with automatic 2-dimensional liquid chromatograph-mass spectrometer coupler 9500 and its application to therapeutic drug monitoring. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000921
Ding, Jing, et al. "Development of a novel analytical method for determining trazodone in human plasma by LC-MS coupled with automatic 2-dimensional liquid chromatograph-mass spectrometer coupler 9500 and its application to therapeutic drug monitoring." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000921
Ding J, Zhang Y, Cui X, Zhao C, Zhang S. Development of a novel analytical method for determining trazodone in human plasma by LC-MS coupled with automatic 2-dimensional liquid chromatograph-mass spectrometer coupler 9500 and its application to therapeutic drug monitoring. Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000921. Epub 2021 Aug 27. PMID: 34469419.
Copy Download .nbib Format: NLM
Drug-drug interactions with OTC medicines: mind the unprescribed.

Therapeutic drug monitoring

Oliver SC.
PMID: 34469416
Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000924. Epub 2021 Aug 27.

PURPOSE: This review provides a summary of the currently available clinical data on drug-drug interactions (DDIs) involving over-the-counter (OTC) medicines. It aims to educate and increase awareness among healthcare providers, and to support decisions in daily practice.METHODS: An extensive...

Cite
Oliver SC. Drug-drug interactions with OTC medicines: mind the unprescribed. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000924.
Oliver, S. C. (2021). Drug-drug interactions with OTC medicines: mind the unprescribed. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000924
Oliver, Scherf-Clavel. "Drug-drug interactions with OTC medicines: mind the unprescribed." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000924
Oliver SC. Drug-drug interactions with OTC medicines: mind the unprescribed. Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000924. Epub 2021 Aug 27. PMID: 34469416.
Copy Download .nbib Format: NLM
Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study.

Therapeutic drug monitoring

Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H.
PMID: 33770020
Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891.

BACKGROUND: Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is...

Cite
Ewoldt TMJ, Abdulla A, Hunfeld NGM, et al. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022;44(1):224-229doi: 10.1097/FTD.0000000000000891.
Ewoldt, T. M. J., Abdulla, A., Hunfeld, N. G. M., Muller, A. E., Gommers, D., Polinder, S., Koch, B. C. P., & Endeman, H. (2022). Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Therapeutic drug monitoring, 44(1), 224-229. https://doi.org/10.1097/FTD.0000000000000891
Ewoldt, Tim M J, et al. "Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study." Therapeutic drug monitoring vol. 44,1 (2022): 224-229. doi: https://doi.org/10.1097/FTD.0000000000000891
Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891. PMID: 33770020.
Copy Download .nbib Format: NLM
Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From Six Phase I Studies.

Therapeutic drug monitoring

Lal R, Ellenbogen A, Gidal B.
PMID: 34726199
Ther Drug Monit. 2021 Nov 01; doi: 10.1097/FTD.0000000000000935. Epub 2021 Nov 01.

BACKGROUND: The absorption and bioavailability of oral gabapentin are associated with a high degree of interindividual variability. Gabapentin enacarbil, a prodrug of gabapentin, is well absorbed and provides sustained, dose-proportional exposure to gabapentin. The aim of this analysis was...

Cite
Lal R, Ellenbogen A, Gidal B. Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From Six Phase I Studies. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000935.
Lal, R., Ellenbogen, A., & Gidal, B. (2021). Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From Six Phase I Studies. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000935
Lal, Ritu, et al. "Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From Six Phase I Studies." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000935
Lal R, Ellenbogen A, Gidal B. Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From Six Phase I Studies. Ther Drug Monit. 2021 Nov 01; doi: 10.1097/FTD.0000000000000935. Epub 2021 Nov 01. PMID: 34726199.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory.

Therapeutic drug monitoring

Shipkova M, Jamoussi H.
PMID: 34726200
Ther Drug Monit. 2021 Nov 01; doi: 10.1097/FTD.0000000000000934. Epub 2021 Nov 01.

PURPOSE: Therapeutic drug monitoring (TDM) of anti-infective drugs is an increasingly complex field, given that in addition to the patient and drug as two usual determinants, its success is driven by the pathogen. Pharmacodynamics is related both to the...

Cite
Shipkova M, Jamoussi H. Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000934.
Shipkova, M., & Jamoussi, H. (2021). Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000934
Shipkova, Maria, and Jamoussi, Hedi. "Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000934
Shipkova M, Jamoussi H. Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Ther Drug Monit. 2021 Nov 01; doi: 10.1097/FTD.0000000000000934. Epub 2021 Nov 01. PMID: 34726200.
Copy Download .nbib Format: NLM
Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites.

Therapeutic drug monitoring

Fay EE, Czuba LC, Sager JE, Shum S, Stephenson-Famy A, Isoherranen N.
PMID: 33814540
Ther Drug Monit. 2021 Dec 01;43(6):780-788. doi: 10.1097/FTD.0000000000000885.

BACKGROUND: Bupropion (BUP) is a chiral antidepressant and smoking cessation aide with benefits and side effects correlated with parent and active metabolite concentrations. BUP is metabolized by CYP2B6, CYP2C19, and CYP3A4 to hydroxy-BUP (OH-BUP) as well as by 11β-hydroxysteroid...

Cite
Fay EE, Czuba LC, Sager JE, et al. Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. Ther Drug Monit. 2021;43(6):780-788doi: 10.1097/FTD.0000000000000885.
Fay, E. E., Czuba, L. C., Sager, J. E., Shum, S., Stephenson-Famy, A., & Isoherranen, N. (2021). Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. Therapeutic drug monitoring, 43(6), 780-788. https://doi.org/10.1097/FTD.0000000000000885
Fay, Emily E, et al. "Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites." Therapeutic drug monitoring vol. 43,6 (2021): 780-788. doi: https://doi.org/10.1097/FTD.0000000000000885
Fay EE, Czuba LC, Sager JE, Shum S, Stephenson-Famy A, Isoherranen N. Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. Ther Drug Monit. 2021 Dec 01;43(6):780-788. doi: 10.1097/FTD.0000000000000885. PMID: 33814540; PMCID: PMC8426418.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 102 entries